Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $15.9 million.

  • Gyre Therapeutics' Total Current Liabilities rose 8.13% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 million, marking a year-over-year increase of 8.13%. This contributed to the annual value of $19.5 million for FY2024, which is 2.65% down from last year.
  • Gyre Therapeutics' Total Current Liabilities amounted to $15.9 million in Q3 2025, which was down 5.95% from $16.9 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Total Current Liabilities ranged from a high of $20.0 million in Q4 2023 and a low of $1.6 million during Q3 2022.
  • Moreover, its 3-year median value for Total Current Liabilities was $15.9 million (2025), whereas its average is $13.9 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 90.47% in 2022, then soared by 725.35% in 2024.
  • Quarterly analysis of 5 years shows Gyre Therapeutics' Total Current Liabilities stood at $14.2 million in 2021, then fell by 13.58% to $12.2 million in 2022, then skyrocketed by 63.76% to $20.0 million in 2023, then fell by 2.65% to $19.5 million in 2024, then grew by 8.13% to $15.9 million in 2025.
  • Its last three reported values are $15.9 million in Q3 2025, $16.9 million for Q2 2025, and $19.0 million during Q1 2025.